David A. Westerman, MBBS, FRCPA, FRACP

Head of Haematopathology
Peter MacCallum Cancer Centre; University of Melbourne, Australia

Poster(s):

• 1514 - Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel B-Cell Lymphoma 2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Demonstrate Deep and Durable Responses